Sepracor Gets DDMAC Letter for Lunesta TV Ad

Sepracor has received an untitled letter from the FDA’s Division of Drug Marketing, Advertising, and Communications (DDMAC) for a direct-to-consumer TV ad that makes unsubstantiated claims about its insomnia drug Lunesta. The boxing-themed ad asks consumers why they would go another round with an ineffective sleep aid when Lunesta (eszopiclone) is “different” and “keys into receptors that support sleep, setting your sleep process in motion.” The claims misleadingly imply the drug is superior to other insomnia medications, DDMAC says.
Washington Drug Letter